Advanced tongue cancer is associated with poor survival despite aggressive therapy het there is a subset amongst these aggressive tumors, which justify radical treatment Advanced tongue cancer is associated with poor survival despite aggressive therapy het there is a subset amongst these aggressive tumors, which justify radical treatment .

Advanced tongue cancer is associated with poor survival despite aggressive therapy het there is a subset amongst these aggressive tumors, which justify radical treatment Advanced tongue cancer is associated with poor survival despite aggressive therapy het there is a subset amongst these aggressive tumors, which justify radical treatment Advanced tongue cancer is associated with poor survival despite aggressive therapy het there is a subset amongst these aggressive tumors, which justify radical treatment Advanced tongue cancer is associated with poor survival despite aggressive therapy het there is a subset amongst these aggressive tumors, which justify radical treatment Advanced tongue cancer is associated with poor survival despite aggressive therapy het there is a subset amongst these aggressive tumors, which justify radical treatment Advanced tongue cancer is associated with poor survival despite aggressive therapy het there is a subset amongst these aggressive tumors, which justify radical treatment Advanced tongue cancer is associated with poor survival despite aggressive therapy het there is a subset amongst these aggressive tumors, which justify radical treatment Advanced tongue cancer is associated with poor survival despite aggressive therapy het there is a subset amongst these aggressive tumors, which justify radical treatment Advanced tongue cancer is associated with poor survival despite aggressive therapy het there is a subset amongst these aggressive tumors, which justify radical treatment Advanced tongue cancer is associated with poor survival despite aggressive therapy het there is a subset amongst these aggressive tumors, which justify radical treatment Advanced tongue cancer is associated with poor survival despite aggressive therapy het there is a subset amongst these aggressive tumors, which justify radical treatment Advanced tongue cancer is associated with poor survival despite aggressive therapy het there is a subset amongst these aggressive tumors, which justify radical treatment Advanced tongue cancer is associated with poor survival despite aggressive therapy het there is a subset amongst these aggressive tumors, which justify radical treatment Advanced tongue cancer is associated with poor survival despite aggressive therapy het there is a subset amongst these aggressive tumors, which justify radical treatment Advanced tongue cancer is associated with poor survival despite aggressive therapy het there is a subset amongst these aggressive tumors, which justify radical treatment Advanced tongue cancer is associated with poor survival despite aggressive therapy het there is a subset amongst these aggressive tumors, which justify radical treatment Advanced tongue cancer is associated with poor survival despite aggressive therapy het there is a subset amongst these aggressive tumors, which justify radical treatment Advanced tongue cancer is associated with poor survival despite aggressive therapy het there is a subset amongst these aggressive tumors, which justify radical treatment Advanced tongue cancer is associated with poor survival despite aggressive therapy het there is a subset amongst these aggressive tumors, which justify radical treatment Advanced tongue cancer is associated with poor survival despite aggressive therapy het there is a subset amongst these aggressive tumors, which justify radical treatment

Know Your Doctor

Dr. Naresh Somani

Merit in Matric Examination (1984)

Qualification : M.B.B.S., M.D. (Medicine)

D.M. (Medical Oncology), Cancer Institute,

Chennai – 1999

Trained at Royal Adelaide Hospital, Australia- 2008­

Scientific Achievement :

1. Published & presented more than 10 International & National Papers in Index Journals.
2. Paper included in “Best Scientific paper award category” in ISMPO conference.
3. Organized international level seminars & Conferences.
4. Established SoMex Research & Health Private Limited
   (A Clinical Research Organization).
5. Conducted more than 15 International Clinical Trials to established new drugs in Cancer Management (Phase 1 to phase 3).
6. Scientific Registrar of Medical Practitioners Society, (2007-2008).
7. Life member of many Oncology Societies.
8. Published “Cancer – Upchar” book
9. Participated & organized more than 150 free cancer detection &
   check up camps.

List of Publications : Dr Naresh  Somani

■ “A pilot study of BEACOPP (Basic & “modified escalated”) chemotherapy with our without involved field radiotherapy in Hodgkin’s disease: A cost effective & risk stratified protocol in Indian context” (Published in Indian Journal of Medical & Paediatric Oncology - ISSN 0971-5851)

■ Activity of specific inhibitor of epidermal growth factor receptor (Gefitinib) in refractory Non-Small-Cell Cancer (NSCLC) - Published in Current Medical Trends - ISSN 0972-3390.

■ Review article: systemic treatment of primary breast cancer JAPI, Vol. No. 49, April, 2001 (ISSN-0004-5772)

■ “Modified BEACOPP regime as a cost-effective therapy for unfavourable Hodgkin’s disease in underprivileged countries” (Shantanu Sharma, Naresh Somani, S.C. Pande, Nidhi Patni). Presented at 38th Annual Conference of the International Society of Paediatric Oncology (SIOP), Geneva, Switzerland, Sept. 2006 and published in “Pediatric Blood & Cancer” Volume 47, Issue 4, Oct. 1, 2006 PJ.017, ISSN 1545-5009

■ Review article: overview of management of primary pulmonary lymphoma, Current Medical Trends (ISSN 0972-3390)

■ Review article, drug review: Topotecan, Journal of Indian Society of Med. & Ped. Oncology, 2001 -  ISSN 0971-5851

■ Effect of climatic variation on flow rates in normal subject and Asthamatics. Somani N., Kotia Amit, Mathur U.S.

■ A comparative study of tobacco consumption (smoking & chewing on certain cardiovascular & metabolic parameters – Somani Naresh, Kotia Amit, Mathur U.S. Rajasthan Medical Journal, India

■ Profile of vertebral secondaries in non-mammary carcinoma; Journal of association of physicians of India – Vol. No. 49, Jan. 2001 (ISSN 0004-5772)

■ Clinical profile of Lung Cancer in Indian Context Thesis (Dissertation), submitted to University of Rajasthan for award degree of M.D., 1996

■ Intravenous  Aflibercept in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant

Dr. Pawan Agrawal Attended International Hematology Society meeting held at Bangkok. He also attended Asia Pacific Lung Cancer Conference held at Hyderabad (A. P. ) and also  chaired a scientfic session on small Cell Lung Cancer.